XML 106 R84.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 26, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   $ (75.0) $ (64.8) $ (224.0) $ (217.8)
Subtotal   131.1 452.0 275.4 609.7
Capitalized share-based compensation costs   (2.4) (2.6) (8.0) (8.5)
Share-based compensation expense included in total costs and expenses   128.7 449.4 267.4 601.2
Income tax effect   (24.2) (98.5) (50.5) (126.5)
Selling, General and Administrative Expense   588.4 788.2 1,723.7 1,941.2
Reata Pharmaceuticals, Inc          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   0.0 387.0 0.0 387.0
Operating expenses $ 393.4        
Selling, General and Administrative Expense 196.4        
Research and development expense asset acquired $ 197.0        
Research and development          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   69.8 217.1 124.5 276.3
Selling, general and administrative          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   61.3 234.9 150.9 333.4
Total share-based compensation expense, net of tax          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   $ 104.5 $ 350.9 $ 216.9 $ 474.7